Synageva BioPharma Corp., a Lexington, MA-based biopharmaceutical company developing therapeutic products for rare disorders, closed a $25m private equity financing.
All of the company’s lead investors participated in the funding.
Synageva intends to use the funds to advance the clinical program for SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a rare and devastating disease.
Led by President and CEO Sanj K. Patel, the company is also continuing to expand the network of physicians and medical professionals that will be instrumental in developing this program and its other rare disease therapeutic candidates, which include two enzyme replacement therapies for Lysosomal Storage Disorders (LSDs) and two non-LSD programs for life-threatening conditions.
FinSMEs
21/03/2011